From Jan 2024 Quarterly
"The study completed dosing as planned in December 2023. A number of animals willnow be subject to a ‘recovery period,’ designed to establish whether any effects seenwith ATL1102 administration revert to normal on cessation of treatment. The animalswill then be subject to pathological analysis to fully assess the effects of ATL1102. TheCompany expects to receive a final study report in mid-2024 and expects to discuss theresults with FDA thereafter. Successful completion of the study may allow Percheron to apply in future for special designations with FDA such as Fast Track Designation and Breakthrough Designation"
Nothing more recent has changed from that, so any time in the next couple months.
- Forums
- ASX - By Stock
- PER
- When US tox study due
When US tox study due, page-5
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
|
|||||
Last
8.3¢ |
Change
-0.002(2.35%) |
Mkt cap ! $74.82M |
Open | High | Low | Value | Volume |
8.3¢ | 8.4¢ | 8.3¢ | $33.95K | 407.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 12164 | 8.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.4¢ | 1366 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 12164 | 0.082 |
2 | 143500 | 0.081 |
2 | 106250 | 0.080 |
3 | 132078 | 0.079 |
2 | 120924 | 0.078 |
Price($) | Vol. | No. |
---|---|---|
0.084 | 1366 | 1 |
0.085 | 136669 | 3 |
0.086 | 27375 | 1 |
0.087 | 429525 | 2 |
0.088 | 457142 | 2 |
Last trade - 15.57pm 03/09/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |